MEDIA, Pa., Jan. 31 /PRNewswire-FirstCall/ -- A new study conducted by Harvard researchers Grodstein, Manson and Stampfer, published in the Journal of Women’s Health, reveals the importance of early treatment of post- menopausal women with hormone replacement therapy (HRT). Results of this study found a distinct advantage to treating women close to menopause with HRT when compared to women initiating HRT a decade or more following menopause. Women starting HRT near menopause enjoyed a 30% reduction in their risk of heart disease when compared to women not taking HRT. A similar benefit was absent in women initiating HRT therapy ten years following menopause. This finding held true for women taking both estrogen only or combination estrogen and progesterone therapy.
The authors conclude that the point at which HRT is initiated in relation to menopause is potentially important with respect to coronary risk. This conclusion contradicts an earlier study (N Engl J Med, 2003) in which HRT was found to potentially increase the risk of coronary heart disease (CHD) in women taking HRT. The difference in outcomes appears to be related to the time point when HRT was initiated following the menopause onset. It is apparent from this study that the benefits of HRT increase if implemented closer to menopause and decline in the decades following menopause.
“This study also inherently highlights the value of an early and accurate diagnosis of menopause,” stated Ron Spangler, PhD, Chief Scientific Officer for Synova Healthcare, Inc. Synova is the maker of Menocheck(R) and MenocheckPro(TM), which are both rapid non-invasive menopause indicator tests, used by consumers and clinicians respectively, for the determination of menopause onset. Menocheck(R) is an over-the-counter test that is widely available at retail chain drugs stores, while MenocheckPro(TM) is a point-of- care diagnostic used by healthcare providers in-office. “We expect both Menocheck(R) and MenocheckPro(TM) to continue to play a vital role in the diagnosis of menopause.”
About Synova Healthcare Group, Inc.:
Synova Healthcare Group, Inc., , presently operates two wholly owned subsidiaries; Synova Healthcare, Inc. and Synova Pre-Natal Healthcare, Inc. The company distributes rapid, non-invasive medical diagnostics to retail for over-the-counter (OTC) use, and directly to health care providers for point of care (POC) use in the clinical setting. The company’s products are designed to improve human health and quality of life by providing early and accurate awareness of the onset of certain medical conditions.
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.
Corporate Contact Information: Synova Healthcare Group, Inc. Attn: Mr. Robert Edwards, CFO 1400 N. Providence Road, Ste. 6010 Media, PA 19063 Tel: 610-565-7080 Fax: 610-565-7081 http://www.synovahealthcare.com Inquiries may also be directed to: info@synovahealthcare.com
Synova Healthcare Group, Inc.
CONTACT: Robert Edwards, CFO of Synova Healthcare Group, +1-610-565-7080,or fax, +1-610-565-7081, info@synovahealthcare.com
Web site: http://www.synovahealthcare.com//
